NZ595294A - Intraocular sustained release drug delivery systems and methods for treating ocular conditions - Google Patents

Intraocular sustained release drug delivery systems and methods for treating ocular conditions

Info

Publication number
NZ595294A
NZ595294A NZ595294A NZ59529410A NZ595294A NZ 595294 A NZ595294 A NZ 595294A NZ 595294 A NZ595294 A NZ 595294A NZ 59529410 A NZ59529410 A NZ 59529410A NZ 595294 A NZ595294 A NZ 595294A
Authority
NZ
New Zealand
Prior art keywords
sustained release
methods
drug delivery
delivery systems
microspheres
Prior art date
Application number
NZ595294A
Other languages
English (en)
Inventor
James A Burke
Werhner C Orilla
Hui Liu
Marianne M Do
Scott Whitcup
Patrick M Hughes
Alazar N Ghebremeskel
Kun Xu
Lon T Spada
Michael R Robinson
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of NZ595294A publication Critical patent/NZ595294A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ595294A 2009-03-25 2010-03-25 Intraocular sustained release drug delivery systems and methods for treating ocular conditions NZ595294A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/411,250 US20100247606A1 (en) 2009-03-25 2009-03-25 Intraocular sustained release drug delivery systems and methods for treating ocular conditions
PCT/US2010/028584 WO2010111449A1 (en) 2009-03-25 2010-03-25 Intraocular sustained release drug delivery systems and methods for treating ocular conditions

Publications (1)

Publication Number Publication Date
NZ595294A true NZ595294A (en) 2013-11-29

Family

ID=42326990

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ595294A NZ595294A (en) 2009-03-25 2010-03-25 Intraocular sustained release drug delivery systems and methods for treating ocular conditions

Country Status (13)

Country Link
US (1) US20100247606A1 (enExample)
EP (1) EP2411013B1 (enExample)
JP (2) JP2012521997A (enExample)
KR (4) KR20170064556A (enExample)
CN (1) CN102497865A (enExample)
AU (3) AU2010229891A1 (enExample)
BR (1) BRPI1012324A2 (enExample)
CA (1) CA2756065A1 (enExample)
IL (1) IL215205A0 (enExample)
MX (1) MX2011009901A (enExample)
NZ (1) NZ595294A (enExample)
RU (2) RU2532333C2 (enExample)
WO (1) WO2010111449A1 (enExample)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US20090148527A1 (en) * 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7947732B2 (en) * 2007-07-13 2011-05-24 Allergan, Inc. Therapeutic substituted chlorocyclopentanols
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
AU2009246520B2 (en) 2008-05-12 2012-04-19 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US20100104654A1 (en) 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
EP2432420A4 (en) 2009-05-18 2018-01-10 Dose Medical Corporation Drug eluting ocular implant
CN102821753A (zh) * 2010-01-22 2012-12-12 阿勒根公司 前房内持续释放治疗药植入物
US10413506B2 (en) 2010-04-03 2019-09-17 Praful Doshi Medical devices including medicaments and methods of making and using same including enhancing comfort, enhancing drug penetration, and treatment of myopia
AU2011233663B2 (en) 2010-04-03 2016-04-14 Praful Doshi Medical devices including medicaments and methods of making and using same
WO2012012546A2 (en) * 2010-07-21 2012-01-26 Allergan, Inc. METHOD OF CONTROLLING INITIAL DRUG RELEASE OF siRNA FROM SUSTAINED-RELEASE IMPLANTS
SG187770A1 (en) 2010-08-12 2013-03-28 Univ Nanyang Tech A liposomal formulation for ocular drug delivery
BR112013003600A2 (pt) * 2010-08-17 2016-08-16 Allergan Inc agonistas ep2 ou ep4 para o tratamento de névoa da córnea
EP2654715B1 (en) 2010-11-24 2017-01-25 Dose Medical Corporation Drug eluting ocular implant
US20120276186A1 (en) 2011-04-29 2012-11-01 Ghebremeskel Alazar N Sustained release latanoprost implant
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
US20130035338A1 (en) * 2011-08-05 2013-02-07 Gordon Tang Eyelid treatment
EP2567689A1 (en) * 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
EP2623490A1 (en) * 2012-02-03 2013-08-07 Fovea Pharmaceuticals 2-(3-aminophenoxy)-acetic acid derivatives as EP2 receptor agonists for use in treatment of glaucoma
EP2570402A1 (en) * 2011-09-16 2013-03-20 Fovea Pharmaceuticals Bi-aryl derivatives, their preparation and their therapeutic application
CA2848229C (en) * 2011-09-16 2019-08-27 Fovea Pharmaceuticals Aniline derivatives, their preparation and their therapeutic application
TWI560172B (en) * 2011-11-02 2016-12-01 Theravance Biopharma R&D Ip Llc Neprilysin inhibitors
EP2950782B1 (en) 2013-01-31 2017-12-27 Icon Bioscience, Inc. Sustained release formulations for the treatment of intraocular pressure or glaucoma
CN104055695B (zh) * 2013-03-22 2016-12-28 深圳市绿蛙生物科技有限公司 中药型快干消毒护手霜及其制备方法
AU2014248460B2 (en) * 2013-04-01 2019-04-11 Allergan, Inc. Microsphere drug delivery system for sustained intraocular release
CA2908731A1 (en) 2013-04-12 2014-10-16 Allergan, Inc. Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction
PT3062775T (pt) 2013-10-31 2018-03-06 Allergan Inc Implantes intraoculares contendo prostamida e métodos para a sua utilização
US20160296627A1 (en) * 2013-12-06 2016-10-13 Envisia Therapeutics Inc. Intracameral implant for treatment of an ocular condition
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
WO2015175544A1 (en) * 2014-05-12 2015-11-19 Allergan, Inc. Quaternary ammonium alkyl esters of prostanoid derivatives as stable prodrugs
AU2015266850B2 (en) 2014-05-29 2019-12-05 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
CN105266952A (zh) * 2014-07-09 2016-01-27 首都医科大学附属北京同仁医院 一种抗青光眼手术中所用防术后结膜粘连的器材
US9931306B2 (en) * 2014-09-06 2018-04-03 Integral Biosystems Llc Methods and biocompatible compositions to achieve sustained drug release in the eye
US10434071B2 (en) 2014-12-18 2019-10-08 Dsm Ip Assets, B.V. Drug delivery system for delivery of acid sensitivity drugs
US10010502B2 (en) 2015-05-19 2018-07-03 Amorphex Therapeutics Llc Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation
KR20260025887A (ko) * 2015-06-06 2026-02-24 클라우드브레이크 테라퓨틱스, 엘엘씨 익상편을 치료하기 위한 조성물 및 방법
CN108883070A (zh) * 2015-07-23 2018-11-23 爱瑞制药公司 用于治疗眼病的玻璃体内药物递送系统
US9820954B2 (en) * 2015-08-19 2017-11-21 Jenivision Inc. Quantitative peri-orbital application of ophthalmology drugs
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
US11458041B2 (en) 2015-10-08 2022-10-04 Ocular Therapeutix, Inc. Punctal plug and bioadhesives
GB201522441D0 (en) 2015-12-18 2016-02-03 Midatech Pharma Wales Ltd Sustained release cyclosporine-loaded microparticles
AU2017252294B2 (en) 2016-04-20 2021-12-02 Glaukos Corporation Bioresorbable ocular drug delivery device
AU2017274195B2 (en) 2016-06-02 2022-04-07 Ads Therapeutics Llc Compositions and methods of using nintedanib for improving glaucoma surgery success
EP3515406B1 (en) * 2016-09-23 2024-07-24 Incept, LLC Intracameral drug delivery depots
CN111050754A (zh) * 2017-07-17 2020-04-21 商福溪生技有限公司 用于递送活性剂的微粒制剂
RU2685499C1 (ru) * 2018-07-19 2019-04-18 федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ лечения прогрессирующей миопии у детей с выявленным привычно-избыточным напряжением аккомодации
WO2020047141A1 (en) * 2018-08-30 2020-03-05 Liu Yunxiang Ophthalmic injectable formulation preparing and oculopathy treating and preventing
PL427837A1 (pl) * 2018-11-22 2020-06-01 Gbj Pharma Spółka Z Ograniczoną Odpowiedzialnością Systemy do ciągłego obwodowego podawania latanoprostu dla obniżania ciśnienia śródgałkowego
KR20210139250A (ko) * 2019-02-08 2021-11-22 오하이오 스테이트 이노베이션 파운데이션 항산화제-방출 유리체 대체물 및 이의 용도
PT3861985T (pt) 2020-02-06 2023-08-03 Ocular Therapeutix Inc Composições e métodos para tratar doenças oculares
PT3884929T (pt) 2020-03-25 2023-08-09 Ocular Therapeutix Inc Implante ocular contendo um inibidor da tirosina cinase
EP4142664A4 (en) 2020-04-27 2024-05-29 Ocular Therapeutix, Inc. METHODS FOR TREATING ALLERGIC CONJUNCTIVITIS
EP4149400B1 (en) * 2020-05-15 2026-04-22 Georgia Tech Research Corporation Methods and compositions for reducing intraocular pressure
AU2021285850A1 (en) * 2020-06-03 2023-02-09 Glaukos Corporation Rho kinase inhibitor releasing implants and related methods of use
EP4288043A1 (en) * 2021-02-05 2023-12-13 Jenivision Inc. Compositions and methods for periorbital administration of ep2 receptor agonists
CN113133431A (zh) * 2021-02-25 2021-07-20 中南大学 慢性高眼压合并长眼轴动物模型的建立方法、模型及应用
PE20260040A1 (es) 2023-04-11 2026-01-09 Ocular Therapeutix Inc Implante ocular que contiene un inhibidor de la tirosina cinasa
AU2024275112A1 (en) * 2023-05-19 2026-01-15 The Trustees Of Columbia University In The City Of New York Treating elevated intraocular pressure with nicotinamide
US12605394B2 (en) 2024-07-25 2026-04-21 Visionary Assets, Llc Compositions containing cannabinoid nanoparticles

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT252264B (de) * 1965-03-17 1967-02-10 Etapharm Chem Pharm Lab Ges M Verfahren zur Herstellung eines reinen hochviskosen Hyaluronsäurepräparates
US3749776A (en) * 1970-08-28 1973-07-31 Allergan Pharma Method for blocking prostaglandin activity
US4403353A (en) * 1981-06-25 1983-09-13 Tennant Jerald L Anterior chamber implant lens
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US5166331A (en) * 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
US6309669B1 (en) * 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US5585401A (en) * 1994-12-09 1996-12-17 The Reents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
US5612027A (en) * 1995-04-18 1997-03-18 Galin; Miles A. Controlled release of miotic and mydriatic drugs in the anterior chamber
US5972326A (en) * 1995-04-18 1999-10-26 Galin; Miles A. Controlled release of pharmaceuticals in the anterior chamber of the eye
US7867186B2 (en) * 2002-04-08 2011-01-11 Glaukos Corporation Devices and methods for treatment of ocular disorders
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
WO2003092665A2 (en) * 2002-05-02 2003-11-13 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
RU2355385C2 (ru) * 2002-11-06 2009-05-20 Алза Корпорейшн Композиции пролонгированного действия с контролируемым высвобождением
US20040193095A1 (en) * 2003-03-29 2004-09-30 Shadduck John H. Implants for treating ocular hypertension, methods of use and methods of fabrication
DE602005011928D1 (de) * 2004-01-20 2009-02-05 Allergan Inc Zusammensetzungen für die lokalisierte therapie des auges, vorzugsweise enthaltend triamcinolon-acetonid und hyaluronsäure
JP2007519724A (ja) * 2004-01-26 2007-07-19 シヴィダ・インコーポレイテッド 核酸を基剤とする治療剤の制御送達および持続的送達
US7799336B2 (en) * 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8147865B2 (en) * 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8722097B2 (en) * 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US7993634B2 (en) * 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20060182781A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US20050244471A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
EP1856042B1 (en) * 2005-03-10 2012-06-27 Allergan, Inc. Substituted gamma lactams as therapeutic agents
MX339797B (es) * 2005-10-18 2016-06-10 Allergan Inc Terapia ocular que usa derivados glucocorticoides que penetran selectivamente los tejidos del segmento posterior.
US7585895B2 (en) * 2005-12-06 2009-09-08 Allergan, Inc. Therapeutic substituted cyclopentanes
US7427685B2 (en) * 2005-12-06 2008-09-23 Allergan, Inc. Therapeutic substituted cyclopentanes
CN101330914A (zh) * 2005-12-16 2008-12-24 爱尔康公司 使用alk5调节剂控制眼内压
EP1978892B1 (en) * 2006-01-17 2017-11-15 Novartis Ag Drug delivery treatment device
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US9039761B2 (en) * 2006-08-04 2015-05-26 Allergan, Inc. Ocular implant delivery assemblies with distal caps
BRPI0714815A2 (pt) * 2006-08-07 2013-05-21 Bausch & Lomb composiÇço, e, uso de um (a) agonista e (b) um agente anti-infeccioso
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8846073B2 (en) * 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
US8722726B2 (en) * 2007-01-25 2014-05-13 Allergan, Inc. Substituted arylcyclopentenes as therapeutic agents
US7589213B2 (en) * 2007-04-27 2009-09-15 Old David W Therapeutic substituted lactams
US11078262B2 (en) * 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
US7947732B2 (en) * 2007-07-13 2011-05-24 Allergan, Inc. Therapeutic substituted chlorocyclopentanols
IL186598A0 (en) * 2007-10-11 2008-11-03 Mohammad Abdulrazik Composition and method for the treatment or prevention of glaucoma and ocular hypertension
MX2010005105A (es) * 2007-11-09 2010-05-27 Allergan Inc Ciclopentanos substituidos que comprenden actividad de prostaglandina.
US20110152328A1 (en) * 2008-04-16 2011-06-23 Whitcup Scott M Combination Therapy For Glaucoma
EP2296621A1 (en) * 2008-05-20 2011-03-23 Yale University Biodegradable sustained-release polymeric microparticulates comprising a hydrophobic drug and determined for ophthalmic use
US20100104654A1 (en) * 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
CN102821753A (zh) * 2010-01-22 2012-12-12 阿勒根公司 前房内持续释放治疗药植入物

Also Published As

Publication number Publication date
RU2532333C2 (ru) 2014-11-10
KR20160120800A (ko) 2016-10-18
WO2010111449A1 (en) 2010-09-30
KR20170064556A (ko) 2017-06-09
RU2664686C2 (ru) 2018-08-21
CN102497865A (zh) 2012-06-13
AU2010229891A1 (en) 2011-10-20
JP2012521997A (ja) 2012-09-20
KR20180108883A (ko) 2018-10-04
CA2756065A1 (en) 2010-09-30
EP2411013A1 (en) 2012-02-01
US20100247606A1 (en) 2010-09-30
JP2015007117A (ja) 2015-01-15
MX2011009901A (es) 2011-11-18
KR20120006998A (ko) 2012-01-19
AU2018211329A1 (en) 2018-08-23
IL215205A0 (en) 2011-12-29
EP2411013B1 (en) 2020-08-19
AU2016231616A1 (en) 2016-10-20
RU2011140433A (ru) 2013-04-27
RU2014133501A (ru) 2016-03-10
BRPI1012324A2 (pt) 2016-03-15

Similar Documents

Publication Publication Date Title
NZ595294A (en) Intraocular sustained release drug delivery systems and methods for treating ocular conditions
Wenk et al. Silk fibroin as a vehicle for drug delivery applications
JP2012521997A5 (enExample)
Abu Owida et al. Advancement of nanofibrous mats and common useful drug delivery applications
NZ619297A (en) Intraocular drug delivery systems
EP1962798B1 (en) Injectable formulation capable of forming a drug-releasing device
WO2008157614A3 (en) Sustained intraocular delivery of drugs from biodegradable polymeric microparticles
UA111162C2 (uk) Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
EP1933881B1 (en) Solid polymer delivery compositions and methods for use thereof
JP6282231B2 (ja) 固化するデポー形成の注入可能な薬物製剤に懸濁される持続放出された生分解性または生体侵食性微小球または微小粒子
JP2018500394A5 (enExample)
JP2010511433A5 (enExample)
WO2010062523A3 (en) Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
JP2008540552A5 (enExample)
BR112012025581A2 (pt) implantes de reservatório de liberação sustentada para distribuição de fármaco intracameral
JP2013523821A5 (enExample)
WO2010061288A3 (en) Polymeric pharmaceutical dosage form in sustained release
MX2013014461A (es) Formulaciones de liberacion sostenida para el suministro de proteinas al ojo y metodos para prepararlas.
WO2010005721A3 (en) Drug loaded polymeric nanoparticles and methods of making and using same
BRPI0510439A (pt) implantes intraoculares de liberação sustentada contendo macromoléculas e métodos relacionados
EP1786400A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE CONTROLLED RELEASE OF BIOLOGICAL ACTIVE SUBSTANCES
FI3655017T3 (fi) Farmaseuttinen koostumus
MX385821B (es) Reduccion de la presion intraocular con implantes de bimatoprost intracamerales.
JP2009535422A5 (enExample)
WO2011112996A3 (en) Injectable drug delivery system

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 25 MAR 2017 BY COMPUTER PACKAGES INC

Effective date: 20140328

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 MAR 2018 BY COMPUTER PACKAGES INC

Effective date: 20170302

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 MAR 2019 BY COMPUTER PACKAGES INC

Effective date: 20180302

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 MAR 2020 BY COMPUTER PACKAGES INC

Effective date: 20190302

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 MAR 2021 BY COMPUTER PACKAGES INC

Effective date: 20200303

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 MAR 2022 BY COMPUTER PACKAGES INC

Effective date: 20210309

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 MAR 2023 BY THOMSON REUTERS

Effective date: 20220302

LAPS Patent lapsed